GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » Interest Coverage

Cutia Therapeutics (HKSE:02487) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Cutia Therapeutics's Operating Income for the six months ended in Dec. 2024 was HK$-255.3 Mil. Cutia Therapeutics's Interest Expense for the six months ended in Dec. 2024 was HK$-6.4 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Cutia Therapeutics's Interest Coverage or its related term are showing as below:


HKSE:02487's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Cutia Therapeutics Interest Coverage Historical Data

The historical data trend for Cutia Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cutia Therapeutics Interest Coverage Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Interest Coverage
- - - -

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Interest Coverage Get a 7-Day Free Trial - - - - -

Competitive Comparison of Cutia Therapeutics's Interest Coverage

For the Biotechnology subindustry, Cutia Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's Interest Coverage falls into.


;
;

Cutia Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cutia Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Cutia Therapeutics's Interest Expense was HK$-11.6 Mil. Its Operating Income was HK$-485.9 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$101.7 Mil.

Cutia Therapeutics did not have earnings to cover the interest expense.

Cutia Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, Cutia Therapeutics's Interest Expense was HK$-6.4 Mil. Its Operating Income was HK$-255.3 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$101.7 Mil.

Cutia Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Cutia Therapeutics  (HKSE:02487) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Cutia Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is a dermatology focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases. Its other products include CU-40102 (topical finasteride spray); CU-10201; CU-40101; and CU-10101 (topical novel small molecule agent) among others. Geographically, the company generates its revenue from the People's Republic of China.
Executives
Zhang Lele 2101 Beneficial owner
Zhang Qiping 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Tong He Yu Cheng Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
6 Dimensions Capital Gp, Llc 2201 Interest of corporation controlled by you
6 Dimensions Capital, L.p. 2101 Beneficial owner
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Yf Dermatology Limited 2101 Beneficial owner
Yunfeng Capital Limited 2102 Investment manager
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you

Cutia Therapeutics Headlines

No Headlines